Literature DB >> 17218844

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Christopher P Crum1, Ronny Drapkin, Alexander Miron, Tan A Ince, Michael Muto, David W Kindelberger, Yonghee Lee.   

Abstract

PURPOSE OF REVIEW: Research over the past 50 years has yielded little concrete information on the source of pelvic serous cancer in women, creating a knowledge gap that has adversely influenced our ability to identify, remove or prevent the earliest stages of the most lethal form of ovarian cancer. RECENT
FINDINGS: The distal fallopian tube is emerging as an established source of many early serous carcinomas in women with BRCA mutations (BRCA+). Protocols examining the fimbrial (SEE-FIM) end have revealed a noninvasive but potentially lethal form of tubal carcinoma, designated tubal intraepithelial carcinoma. Tubal intraepithelial carcinoma is present in many women with presumed ovarian or peritoneal serous cancer. A candidate precursor to tubal intraepithelial carcinoma, entitled the 'p53 signature', suggests that molecular events associated with serous cancer (p53 mutations) may be detected in benign mucosa.
SUMMARY: A fully characterized precursor lesion is a first and necessary step to pelvic serous cancer prevention. The emerging data offer compelling evidence for a model of 'fimbrial-ovarian' serous neoplasia, and call attention to the distal fallopian tube as an important source for this disease, the study of which could clarify pathways to cancer in both organs and generate novel strategies for cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218844     DOI: 10.1097/GCO.0b013e328011a21f

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  168 in total

1.  Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Authors:  Elisabetta Kuhn; Alan Meeker; Tian-Li Wang; Ann Smith Sehdev; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

Review 2.  The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer.

Authors:  Vladimir Djedovic; Yoo-Young Lee; Alexandra Kollara; Taymaa May; Theodore J Brown
Journal:  Horm Cancer       Date:  2018-01-08       Impact factor: 3.869

3.  Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.

Authors:  Daichi Maeda; Satoshi Ota; Yutaka Takazawa; Kenichi Ohashi; Masaya Mori; Tetsuo Imamura; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama
Journal:  Virchows Arch       Date:  2010-09-25       Impact factor: 4.064

4.  Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.

Authors:  Wenxin Zheng; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

5.  Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal?

Authors:  T J Herzog; H E Dinkelspiel
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

6.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

7.  Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis.

Authors:  Ying Wang; Kathy Qi Cai; Elizabeth R Smith; Toni M Yeasky; Robert Moore; Parvin Ganjei-Azar; Andres J Klein-Szanto; Andrew K Godwin; Thomas C Hamilton; Xiang-Xi Xu
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

Review 8.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

9.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

Review 10.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.